Aureka raises $100M to build a biological world model for drug discovery

Granite Asia backed the first tranche as Aureka expands OpenDDE and its wet-lab feedback system for antibody discovery.

By · Published

Primary source: PR Newswire

Why it matters

Aureka is betting that proprietary wet-lab feedback will matter as much as model scale in AI drug discovery. The $100 million round funds a direct test of that thesis.

An extreme close-up of the textured surface of a scientific microscope slide, with a hint of a micro-droplet. (Macro photograph – extreme close-up of a physical lab object, razor-thin focus plane, pronounced material texture.)

Weian Zhao, the founder and CEO of Aureka Biotechnologies, closed a $100 million Series B on August 10th to train larger biological foundation models and connect them more tightly to the experiments that determine whether their molecular designs work.…

When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.

Reader comments

Conversation for this story loads after sign-in.